- $641.23m
- $487.49m
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec
Candel Therapeutics Q4 operating loss misses analyst expectations
Brief: Candel Therapeutics Q4 Net Income USD -29.496 Million
Brief: Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock
U.S. STOCKS ON THE MOVE-Homebuilders, solar stocks, Alphabet
U.S. STOCKS ON THE MOVE-Comfort Systems, Funko, Paymentus
U.S. STOCKS ON THE MOVE-Deckers Outdoor, CDT Equity, Comfort Systems
U.S. STOCKS ON THE MOVE-Akamai, Grail, Candel Therapeutics
Candel Therapeutics drops after $100 mln equity offering
Brief: Candel Therapeutics Announces Pricing Of Public Offering Of 18,348,624 Shares At $5.45 Each
Brief: Candel Therapeutics Announces Proposed $100 Million Public Offering